1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Generic Oncology Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue

Driven by rising cancer incidences, patent expiry of a number of blockbuster oncology drugs and the high cost of cancer treatment, the market for generic oncology drugs has been witnessing robust growth. Apart from their strong growth, these drugs also enjoy high product differentiation and entry barriers. As a result, competitive intensity in this segment is also relatively low. This has enabled manufacturer to enjoy higher pricing power and margins compared to commoditised generics.

IMARC’s latest study “Generic Oncology Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue” provides a comprehensive roadmap for stakeholders who are planning to setup and run a generic drug manufacturing plant. Aspects such as market size, industry trends, manufacturers, land, construction, machinery, labour, investments, revenues, rate of return, margins, etc. have been thoroughly covered in this report

Key Questions Answered in This Report?

What are the historical, current and future trends in the generic market?
What are the historical, current and future trends in the generic oncology market?
What is the competitive structure of the generic market and who are the key players?
What is the competitive structure of the generic oncology market and who are the key players?
What are the key success factors for generic oncology drug manufacturers?
How are generic oncology drugs manufactured?
What are the raw material requirements and their cost for manufacturing generic oncology drugs?
What are the land and construction requirements and their cost for manufacturing generic oncology drugs?
What are the machinery requirements and their cost for manufacturing generic oncology drugs?
What are the packaging requirements and their cost for manufacturing generic oncology drugs?
What are the utility requirements and their cost for manufacturing generic oncology drugs?
What are the manpower requirements and their cost for manufacturing generic oncology drugs?
What is the total capital investment required for setting up a generic oncology drug manufacturing plant
What are the operational costs for setting up a generic oncology drug manufacturing plant?
How much income will the generic oncology drug manufacturing plant generate?
What will be the profitability of the generic oncology drug manufacturing plant?
What will be the NPV of the generic oncology drug manufacturing plant?
What will be the payback period of the generic oncology drug manufacturing plant?

Table Of Contents

Generic Oncology Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue
1 Research Methodology
2 Report Summary
3 Introduction
4 Global Generic Drug Market
4.1 Classification of Generic Drugs
4.2 Market Trends
4.2.1 Current and Historical Market Trends
4.2.2 Market Breakup by Region
4.2.3 Major Players in the Generic Drug Industry
4.2.4 Market Forecast
4.3 Value Chain Analysis of Generic Drugs
4.4 Key Success Factors Driving the Generic Drug Industry
4.6 Regulations in the Generic Drug Industry
5 Global Cancer Generics Market
5.1 Global Cancer Statistics
5.2 Current and Historical Market Trends
5.3 Top Cancer Drugs
5.4 Top Players in the Cancer Generics Market
5.5 Market Forecast
6 Manufacturing Process
6.1 Detailed Process Flow (Tablet)
6.2 Detailed Process Flow (Injectables)
6.3 Cancer Generic Manufacturing Plant: Raw Material Requirements
6.3.1 Cancer Generic Drug (Tablet)
6.3.2 Cancer Generic Drug (Injectables)
7 Project Details, Requirements and Costs Involved
7.1 Land, Location and Site Development
7.2 Plant Machinery
7.3 Machinery Pictures
7.4 Raw Materials
7.5 Packaging
7.6 Utilities
7.7 Manpower
7.8 Other Capital Investments
8 Cancer Generic Drug Manufacturing Plant: Project Economics
8.1 Capital Cost of the Project
8.2 Loans and Financial Assistance
8.3 Techno-Economic Parameters
8.4 Product Pricing
8.5 Income Projections
8.6 Expenditure Projections
8.7 Financial Analysis

List of Figures

Figure 1 1: Global: Cancer Incidence: Breakup by Country (in %), 2014
Figure 4 1: Global: Generics Market: Sales Value (in US$ Billion), 2010-2014
Figure 4 2: Global: Generics Market: Breakup by Country (in %), 2014
Figure 4 3: Global: Generics Market: Sales Value (in US$ Billion), 2015-2020
Figure 4 4: Global: Generics Market: Value Chain
Figure 5 1: Global: Cancer Incidence: 2007-2014
Figure 5 2: Global: Cancer Incidence: Breakup by Country (in %), 2014
Figure 5 3: Global: Cancer GenericsMarket: Sales Value (in US$ Billion), 2007-2014
Figure 5 4: Global: Cancer Generics Market Forecast: Sales Value (in US$ Billion), 2015-2020
Figure 6 1: Cancer Generic (Tablet) Manufacturing: Detailed Process Flow
Figure 6 2: Cancer Generic (Injectable) Manufacturing: Detailed Process Flow
Figure 6 3: Cancer Generic (Imatinib Tablet) Manufacturing Process: Conversion Rate of Feedstocks
Figure 6 4: Cancer Generic (Paclitaxel) Manufacturing Process: Conversion Rate of Feedstocks
Figure 7 1: Cancer Generic Manufacturing Plant: Primary Packaging
Figure 7 2: Cancer Generic Manufacturing Plant: Secondary Packaging
Figure 7 3: Cancer Generic Manufacturing Plant: Tertiary Packaging
Figure 8 1: Cancer Generic Manufacturing Plant: Breakup of Capital Costs (in %)
Figure 8 2: Cancer Generic Manufacturing Plant: Breakup of Production Costs (in %)

List of Tables

Table 4 1: Global: Generics Market: Revenues of Key Players (in US$ Billion), 2014
Table 7 1: Cancer Generic Manufacturing Plant: Costs Related to Land and Site Development (in US$)
Table 7 2: Cancer Generic Manufacturing Plant: Costs Related to Civil Works (in US$)
Table 7 3: Cancer Generic Manufacturing Plant: Machinery Costs (in US$)
Table 7 4: Cancer Generic Manufacturing Plant: Raw Material Requirements (in Kg/Day)
Table 7 5: Cancer Generic Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 7 6: Cancer Generic Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
Table 8 1: Cancer Generic Manufacturing Plant: Capital Costs (in US$)
Table 8 2: Details of Financial Assistance Offered by Financial Institutions
Table 8 3: Cancer Generic Manufacturing Plant: Loan Installments
Table 8 4: Cancer Generic Manufacturing Plant: Techno- Economic Parameters
Table 8 5: Cancer Generic Manufacturing Plant: Income Projections (in US$)
Table 8 6: Cancer Generic Manufacturing Plant: Expenditure Projections (in US$)
Table 8 7: Cancer Generic Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
Table 8 8: Cancer Generic Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Cancer Diagnostic Testing Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology

2016 Europe Cancer Diagnostic Testing Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

Europe Cancer Diagnostics Market 2017-2021:  France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies

Europe Cancer Diagnostics Market 2017-2021: France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies

  • $ 12800
  • Industry report
  • December 2016
  • by Venture Planning Group

Complete report $19,700.DataPack (test volumes, sales forecasts, supplier shares) $12,800. Summary This comprehensive five-country report contains 820 pages, 320 tables, and presents analysis of the majo ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Therapy Market in the UK

  • January 2017
    14 pages
  • Therapy  

    Chemotherapy  

  • United Kingdom  

View report >

Related Market Segments :

Cancer
Oncology

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.